header logo image header logo text
Downloads Login
Research
General Information
ZIRC
ZFIN ID: ZDB-FISH-150901-7764
Fish name: gz15Tg; gz26Tg
Genotype: gz15Tg; gz26Tg
Targeting Reagent: none
HUMAN DISEASE MODELED by gz15Tg; gz26Tg
Human Disease Conditions Citations
hepatocellular carcinoma chemical treatment: doxycycline Yan et al., 2017
GENE EXPRESSION
Gene expression in gz15Tg; gz26Tg
RNA expression No data available
Protein expression
Antibody Antigen Genes Structure Conditions Figures
Ab6-pcna chemical treatment: doxycycline Fig. 4 with image from Yan et al., 2017
PHENOTYPE
Phenotype in gz15Tg; gz26Tg
Phenotype Conditions Figures
hepatocyte nucleolus increased amount, abnormal chemical treatment: doxycycline, chemical treatment: Cyclopamine Fig. 6 with image from Yan et al., 2017
hepatocyte nucleolus increased amount, abnormal chemical treatment: doxycycline Fig. 6 with image from Yan et al., 2017
hepatocyte nucleus size, abnormal chemical treatment: doxycycline Fig. 6 with image from Yan et al., 2017
hepatocyte nucleus size, abnormal chemical treatment: doxycycline, chemical treatment: Cyclopamine Fig. 6 with image from Yan et al., 2017
hepatocyte vacuole increased amount, abnormal chemical treatment: doxycycline Fig. 6 with image from Yan et al., 2017
hepatocyte vacuole increased amount, abnormal chemical treatment: doxycycline, chemical treatment: Cyclopamine Fig. 6 with image from Yan et al., 2017
liver ab6-pcna labeling amount, ameliorated chemical treatment: IWR-1-endo, chemical treatment: doxycycline Fig. 4 with image from Yan et al., 2017
liver ab6-pcna labeling amount, ameliorated chemical treatment: doxycycline, chemical treatment: SU5402 Fig. 4 with image from Yan et al., 2017
liver circular, abnormal chemical treatment: doxycycline Fig. 1 with image from Yan et al., 2017
liver hyperplastic, abnormal chemical treatment: doxycycline, chemical treatment: Cyclopamine Fig. 6 with image from Yan et al., 2017
liver hyperplastic, abnormal chemical treatment: doxycycline Fig. 6 with image from Yan et al., 2017
liver hyperplastic, ameliorated chemical treatment: IWR-1-endo, chemical treatment: doxycycline Fig. 6 with image from Yan et al., 2017
liver hyperplastic, ameliorated chemical treatment: doxycycline, chemical treatment: SU5402 Fig. 6 with image from Yan et al., 2017
liver ab6-pcna labeling increased amount, abnormal chemical treatment: doxycycline, chemical treatment: Cyclopamine Fig. 4 with image from Yan et al., 2017
liver ab6-pcna labeling increased amount, abnormal chemical treatment: doxycycline Fig. 4 with image from Yan et al., 2017
liver increased size, abnormal chemical treatment by environment: doxycycline Fig. 2 with image from Zhao et al., 2016
liver increased size, abnormal chemical treatment: doxycycline, chemical treatment: GANT61 Fig. 3 with image from Yan et al., 2017
liver increased size, abnormal chemical treatment: doxycycline, chemical treatment: Cyclopamine Fig. 3 with image from Yan et al., 2017
liver increased size, abnormal chemical treatment: doxycycline Fig. 1 with imageFig. 2 with imageFig. 3 with image from Yan et al., 2017
liver increased size, abnormal chemical treatment: drug Fig. 1 with image from Li et al., 2013
liver size, ameliorated chemical treatment: doxycycline, chemical treatment: orantinib Fig. 1 with image from Yan et al., 2017
liver size, ameliorated chemical treatment: IWR-1-endo, chemical treatment: doxycycline Fig. 2 with image from Yan et al., 2017
liver size, ameliorated chemical treatment: doxycycline, chemical treatment: cardionogen-1 Fig. 2 with image from Yan et al., 2017
liver size, ameliorated chemical treatment: doxycycline, chemical treatment: SU5402 Fig. 1 with image from Yan et al., 2017
liver size, ameliorated chemical treatment by environment: doxycycline, chemical treatment by environment: sunitinib Fig. 2 with image from Zhao et al., 2016
liver size, ameliorated chemical treatment by environment: doxycycline, chemical treatment by environment: semaxanib Fig. 2 with image from Zhao et al., 2016
liver apoptotic process increased occurrence, abnormal chemical treatment: doxycycline, chemical treatment: Cyclopamine Fig. 5 with image from Yan et al., 2017
liver apoptotic process increased occurrence, abnormal chemical treatment: doxycycline Fig. 5 with image from Yan et al., 2017
liver apoptotic process increased occurrence, ameliorated chemical treatment: doxycycline, chemical treatment: SU5402 Fig. 5 with image from Yan et al., 2017
liver apoptotic process increased occurrence, ameliorated chemical treatment: IWR-1-endo, chemical treatment: doxycycline Fig. 5 with image from Yan et al., 2017
liver cell population proliferation increased occurrence, abnormal chemical treatment: doxycycline, chemical treatment: Cyclopamine Fig. 4 with image from Yan et al., 2017
liver cell population proliferation increased occurrence, abnormal chemical treatment: doxycycline Fig. 4 with image from Yan et al., 2017
liver cell population proliferation increased occurrence, ameliorated chemical treatment: IWR-1-endo, chemical treatment: doxycycline Fig. 4 with image from Yan et al., 2017
liver cell population proliferation increased occurrence, ameliorated chemical treatment: doxycycline, chemical treatment: SU5402 Fig. 4 with image from Yan et al., 2017

CITATIONS  (5)